University of Hertfordshire

From the same journal

By the same authors

Metabolism of ticagrelor in patients with acute coronary syndromes.

Research output: Contribution to journalArticlepeer-review

Standard

Metabolism of ticagrelor in patients with acute coronary syndromes. / Adamski, Piotr; Buszko, Katarzyna; Sikora, Joanna; Niezgoda, Piotr; Barańska, Malwina ; Ostrowska, Małgorzata; Paciorek, Przemysław; Navarese, Eliano P; Gorog, Diana; Kubica, Jacek.

In: Scientific Reports, Vol. 8, 11746, 06.09.2018, p. 1-8.

Research output: Contribution to journalArticlepeer-review

Harvard

Adamski, P, Buszko, K, Sikora, J, Niezgoda, P, Barańska, M, Ostrowska, M, Paciorek, P, Navarese, EP, Gorog, D & Kubica, J 2018, 'Metabolism of ticagrelor in patients with acute coronary syndromes.', Scientific Reports, vol. 8, 11746, pp. 1-8. https://doi.org/10.1038/s41598-018-29619-9

APA

Adamski, P., Buszko, K., Sikora, J., Niezgoda, P., Barańska, M., Ostrowska, M., Paciorek, P., Navarese, E. P., Gorog, D., & Kubica, J. (2018). Metabolism of ticagrelor in patients with acute coronary syndromes. Scientific Reports, 8, 1-8. [11746]. https://doi.org/10.1038/s41598-018-29619-9

Vancouver

Adamski P, Buszko K, Sikora J, Niezgoda P, Barańska M, Ostrowska M et al. Metabolism of ticagrelor in patients with acute coronary syndromes. Scientific Reports. 2018 Sep 6;8:1-8. 11746. https://doi.org/10.1038/s41598-018-29619-9

Author

Adamski, Piotr ; Buszko, Katarzyna ; Sikora, Joanna ; Niezgoda, Piotr ; Barańska, Malwina ; Ostrowska, Małgorzata ; Paciorek, Przemysław ; Navarese, Eliano P ; Gorog, Diana ; Kubica, Jacek. / Metabolism of ticagrelor in patients with acute coronary syndromes. In: Scientific Reports. 2018 ; Vol. 8. pp. 1-8.

Bibtex

@article{0b8d0ead0f2941e599a05a2b689bf0d7,
title = "Metabolism of ticagrelor in patients with acute coronary syndromes.",
abstract = "Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized by hepatic CYP3A enzymes, and AR-C124910XX is its only active metabolite. A post hoc analysis of patient-level (n = 117) pharmacokinetic data pooled from two prospective studies was performed to identify clinical characteristics affecting the degree of AR-C124910XX formation during the first six hours after 180 mg ticagrelor loading dose in the setting of ACS. Both linear and multiple regression analyses indicated that ACS patients presenting with ST-elevation myocardial infarction or suffering from diabetes mellitus are more likely to have decreased rate of ticagrelor metabolism during the acute phase of ACS. Administration of morphine during ACS was found to negatively influence transformation of ticagrelor into AR-C124910XX when assessed with linear regression analysis, but not with multiple regression analysis. On the other hand, smoking appears to increase the degree of ticagrelor transformation in ACS patients. Mechanisms underlying our findings and their clinical significance warrant further research.",
author = "Piotr Adamski and Katarzyna Buszko and Joanna Sikora and Piotr Niezgoda and Malwina Bara{\'n}ska and Ma{\l}gorzata Ostrowska and Przemys{\l}aw Paciorek and Navarese, {Eliano P} and Diana Gorog and Jacek Kubica",
note = "{\textcopyright} The Author(s) 2018",
year = "2018",
month = sep,
day = "6",
doi = "10.1038/s41598-018-29619-9",
language = "English",
volume = "8",
pages = "1--8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Metabolism of ticagrelor in patients with acute coronary syndromes.

AU - Adamski, Piotr

AU - Buszko, Katarzyna

AU - Sikora, Joanna

AU - Niezgoda, Piotr

AU - Barańska, Malwina

AU - Ostrowska, Małgorzata

AU - Paciorek, Przemysław

AU - Navarese, Eliano P

AU - Gorog, Diana

AU - Kubica, Jacek

N1 - © The Author(s) 2018

PY - 2018/9/6

Y1 - 2018/9/6

N2 - Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized by hepatic CYP3A enzymes, and AR-C124910XX is its only active metabolite. A post hoc analysis of patient-level (n = 117) pharmacokinetic data pooled from two prospective studies was performed to identify clinical characteristics affecting the degree of AR-C124910XX formation during the first six hours after 180 mg ticagrelor loading dose in the setting of ACS. Both linear and multiple regression analyses indicated that ACS patients presenting with ST-elevation myocardial infarction or suffering from diabetes mellitus are more likely to have decreased rate of ticagrelor metabolism during the acute phase of ACS. Administration of morphine during ACS was found to negatively influence transformation of ticagrelor into AR-C124910XX when assessed with linear regression analysis, but not with multiple regression analysis. On the other hand, smoking appears to increase the degree of ticagrelor transformation in ACS patients. Mechanisms underlying our findings and their clinical significance warrant further research.

AB - Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized by hepatic CYP3A enzymes, and AR-C124910XX is its only active metabolite. A post hoc analysis of patient-level (n = 117) pharmacokinetic data pooled from two prospective studies was performed to identify clinical characteristics affecting the degree of AR-C124910XX formation during the first six hours after 180 mg ticagrelor loading dose in the setting of ACS. Both linear and multiple regression analyses indicated that ACS patients presenting with ST-elevation myocardial infarction or suffering from diabetes mellitus are more likely to have decreased rate of ticagrelor metabolism during the acute phase of ACS. Administration of morphine during ACS was found to negatively influence transformation of ticagrelor into AR-C124910XX when assessed with linear regression analysis, but not with multiple regression analysis. On the other hand, smoking appears to increase the degree of ticagrelor transformation in ACS patients. Mechanisms underlying our findings and their clinical significance warrant further research.

U2 - 10.1038/s41598-018-29619-9

DO - 10.1038/s41598-018-29619-9

M3 - Article

VL - 8

SP - 1

EP - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 11746

ER -